TNFSF11 and plasma cell myeloma: Recombinant OPG constructs, soluble RANK, OPG peptidomimetics [54,55], and, more recently, anti-RANKL antibodies such as denosumab have been developed to modulate the RANKL–OPG axis and reduce osteoclastic activity and myeloma [56,57,58].